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Abstract 
Purpose: To determine the association between Cystatin C (Cys C) levels and the interaction of 
pulmonary tuberculosis (PTB) with chronic diseases (CD). 
Methods: Participants (n = 356) were selected randomly from The First Affiliated Hospital of Wannan 
Medical College, China, and divided into 4 groups: normal control group (n = 80), PTB group (n = 98), 
chronic disease group (n = 146), and PTB combined with chronic disease group (PTB+CD, n = 31). The 
investigation included information on demographics and analysis of blood samples for Cys C, liver 
function, renal function, blood glucose and other biochemical indices.  
Results: The highest level of Cys C was obtained in PTB + CD group. Before and after adjusting eGFR, 
there was no association between Cys C and PTB or/and chronic disease. However abnormal levels of 
Cys C were significantly higher in PTB+CD group after adjusting eGFR (OR = 4.014, p = 0.0125).  
Conclusion: Higher levels of Cys C may be associated with chronic diseases co-existing with PTB. 
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Pulmonary tuberculosis (PTB) is a serious threat 
to human health and there are approximately one 
third of the world’s population are latently 
infected M. tuberculosis [1]. Despite expansion of 
directly observed treatment short course strategy 
and substantial investments aimed at 
improvements in treatment completion rates, 
inaccurate diagnosis remains one of the biggest 
obstacles to global tuberculosis control. Due to 
the high prevalence of cardiovascular diseases 
(CVD), public health programs are confronted 
with the challenge of epidemic of CVD and 
overlapping tuberculosis [2].   
 
Cys C is produced by all nucleated cells and 
removed from the bloodstream by glomerular 
filtration [3]. It is recognized as a marker for 
detecting glomerular function chronic kidney 
disease (CKD), acute kidney injury and related 
sequelae [4-6]. Studies also show that Cys C is 
related to cardiovascular diseases, such as 
cardiac accident and coronary artery disease [7]. 
Cys C is implicated in chronic low-grade 
inflammation in the pathogenesis of 
atherosclerosis. A causal link between increased 
Cys C concentrations and impaired 
cardiovascular outcome has been proposed 
[5,6,8].  
 
Recent studies found that serum Cys C may 
affect the stability of plaques among patients with 
normal kidney function, and may be associated 
with increased carotid plaque burden [9]. It has 
also been reported that Cys C levels in diabetic 
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patients are higher than the levels in healthy non-
diabetics [10]. The pathogenic role of 
Mycobacterium tuberculosis is also related to 
inflammation caused by proliferation of bacteria, 
as well as body impairment produced due to 
delayed type hypersensitivity reaction [11]. An 
important survival mechanisms of 
Mycobacterium tuberculosis is preventing contact 
with active cathepsins by inhibiting phagosome 
maturation [12]. It is known that some cathepsins 
(cathepsin B, D and S) interact and contribute to 
the destruction of invading microorganisms [13]. 
Consistent with the role of Cys C as a natural 
inhibitor of cathepsins, cystatin is down-regulated 
in macrophages infected with Mycobacterium 
tuberculosis. Indeed, treatment with cystatin led 
to a significant 5-fold increase in Mycobacterium 
tuberculosis survival rate after 24h of infection in 
resting macrophages [14]. Down - regulation of 
cathepsin in macrophages induced by 
Mycobacterium tuberculosis. The increase in 
gene expression most of the cystatins was 
observed, although there is an increased 
cathepsin gene expression, a concomitant 
increment of Cys C should impair their activities 
in IFNγ- activated macrophages [14]. 
 
However, there are limited studies on the levels 
of Cys C in patients with PTB combined with 
chronic diseases (hypertension, diabetes and 
cardiovascular disease). In this context, we 
propose a hypothesis that Mycobacterium 
tuberculosis patients with cardiovascular 
diseases may have higher level of Cys C. 
Therefore in this study, the Cys C levels of 
patients with PTB, chronic diseases, and PTB 





Study subjects  
 
All participants in the control and case groups 
were randomly selected from the First Affiliated 
Hospital of Wannan Medical College. Healthy 
individuals without PTB and chronic diseases 
(hypertension, diabetes and cardiovascular 
disease) were in the control group (NC, n = 80). 
The case groups included PTB (n = 98), PTB 
with chronic diseases group (PTB + CD, n = 31) 
and chronic diseases group (CD, n = 146). All 
participants satisfied these conditions: (1) no 
history of liver dysfunction, and (2) no tumor 
history. The study was conducted in compliance 
with Helsinki guidelines of the Helsinki 
Declaration of World Medical Association [15], 
and according to the protocol approved by 
Medical Ethics Committee of Wannan Medical 
College (approval no. 2014005). All participants 
were told the study objective and they gave 
verbal informed consent prior to commencement 
of the investigation. 
 
Assay of Cys C and other biochemical 
indices 
 
Venous blood samples were taken from the 
participants after overnight fast, and sera were 
separated after centrifugation at room 
temperature. The serum samples obtained were 
assayed for Cys C, liver function parameters, 
renal function parameters, blood glucose and 
other biochemical indices using latex enhanced 
transmission immunoassay.  
 
Estimated glomerular filtration rate (eGFR: 
ml/min/1.73 m2) was calculated by Modification 
of Diet in Renal Disease (MDRD) formula (Eq 1) 
[16]. 
 
eGFR = 175× (Cr/88.41)−1.154 × Age−0.203 (×0.742 
if female) ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ (1) 
 
Serum Cys C was determined by 
immunoturbidimetric assay. Normal reference 
rangs of Cy C are 0.54 - 1.14 and 0.63 - 1.25 
(mg/L) in females and males, respectively. 
 
Serum creatinine (Cr) was determined by isotope 
dilution mass spectrometry (IDMS) method. The 
normal reference ranges of creatinine are 44.00 - 
80.00 and 62.00 - 106.00 (μmol/L) in females 
and males, respectively.  
 
Blood urea nitrogen (BUN) was determined by 
urease method, and its normal reference value is 
2.14 - 8.21 mmol/L. 
 





These included confirmed cases such as sputum 
smear positive PTB cases, only-sputum culture- 
positive PTB cases and cases with pulmonary 
lesions of TB that have been confirmed by 
pathological examination [17]. Smear positive 
PTB met one of the following three criteria: Two 
sputum specimens directly smear positive for 
anti-acid bacteria microscopic examination; a 
sputum smear positive direct microscopic 
examination, and lung imaging consistent with 
active PTB imaging manifestation and one 
positive direct smear microscopy result plus one 
positive sputum culture for M. tuberculosis; Only-
culture positive PTB met two criteria namely: 
negative sputum smears and lung imaging 
consistent with active PTB imaging 
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manifestations plus one positive sputum culture 




Systolic blood pressure ≥ 140 mmHg or diastolic 
blood pressure ≥ 90 mmHg, or if participant was 
at that time on medication to control blood 




Fasting blood glucose ≥ 7.1 mmol/L or if patient 
was at that time on drug to control blood glucose 
[19]. 
 
Carotid artery disease 
 
Near and far walls of the common carotid, and 
internal carotid artery on both sides were 
scanned for hemodynamics with 5 -13 MHz 
linear-array probes (Aloka - a7 and Aloka - a10, 
Japan; Philips - IU22, America) [20]. 
 
Coronary heart disease 
 
Coronary angiography was based on standard 
Judkins technique [21] by cardiologists who have 




Data were analyzed statistically using SPSS 18 
software. Differences in demographic 
characteristics were analyzed by chi-square test, 
while ANOVA was used to analyze differences in 
age, Cys C content, BUN and eGFR among the 
four groups. For unadjusted and adjusted eGFR, 
non-conditional logistic regression analysis was 
used to analyze the relationship between chronic 
disease, PTB and Cys C. The relationship 
between Cys C and eGFR was analyzed with 
linear regression analysis. A two-tailed p value 




Characteristics of subjects 
 
Table 1 shows that Cys C and eGFR were 
significantly different among control group, PTB 
group, chronic diseases group and PTB + CD 
group. The levels of Cys C were highest in the 
PTB + CD group, while levels of eGFR were 
lowest in this group (PTB + CD group). There 
were no significant differences in sex, age and 
BUN among the four groups. 
 
Relationship between chronic disease 
and pulmonary tuberculosis, and their 
interaction with Cys C 
 
Table 2 shows that Cys C levels were not 
significantly related to chronic disease or PTB 
regardless of whether eGFR was adjusted or not, 
but Cys C level in the PTB +CD group was 4.014 
times (χ2 = 6.2401, p = 0.0125) higher than that 
of the control group after adjusting eGFR. 
 
Relationship between Cys C and eGFR 
 
The relationship between Cys C and eGFR is 
depicted in Figure 1. Cys C and eGFR were 
negatively correlated in the four groups: Cys C 
increased with decrease in eGFR. 
 











Sex Female 27(27.55%) 40(27.40%) 9(29.03%) 22(27.50%) 0.0353 0.9983 
 Male 71(72.45%) 106(72.60%) 22(70.97%) 58(72.50%)   
Age 53.7018.85 53.5415.90 53.5217.84 59.0011.60 2.3200 0.0750 
Cys C 1.060.29 1.010.26 1.350.53 1.130.33 9.7100 <0.0001 
BUN 5.632.51 5.561.41 6.977.62 5.891.91 2.0200 0.1110 
eGFR 107.8531.47 101.5224.51 90.0925.81 95.5221.41 3.9600 0.0086 
Cys C: cystatin C; BUN: blood urea nitrogen; CRP: C-reactive protein; eGFR: glomerular filtration rate 
 
Table 2: Logistic analysis of chronic disease, tuberculosis and their interaction with the logistic analysis of 
cystatin C 
 
Variable  Unadjusted Adjusted 
χ2 P OR(95%CI) χ2 P OR(95%CI) 
CD 1.0655 0.3020 0.684(0.333-1.406) 0.3022 0.5825 1.809(0.380-1.723) 
PTB 1.3941 0.2377 0.623(0.284-1.366) 0.0229 0.8798 0.938(0.407-2.161) 
PTB+CD 3.6187 0.0571 2.489(0.973-6.368) 6.2401 0.0125 4.014(1.349-11.942) 
Intercept 10.4948 0.0012  9.2737 0.0023  
Adjusted factor: eGFR 
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Figure 1: Relationship between Cys C (mg/L) and eGFR (ml/min/1.73 m2). Cys C was negatively 





The prevention and treatment of tuberculosis 
have become more difficult with global increase 
in drug-resistant tuberculosis. With lifestyle 
transformations and rapid development of the 
global economy, the incidence of chronic 
diseases has continued to grow rapidly, with 
more tuberculosis patients having chronic 
diseases. Thus it is necessary to improve 
prevention and treatment strategies for 
tuberculosis patients with chronic diseases. 
 
This study shows the association between Cys C 
and interaction of tuberculosis with chronic 
diseases. The levels of Cys C were highest in the 
PTB + CD group. Cys C levels were not 
significantly related with chronic disease or PTB 
regardless of whether eGFR was adjusted or not. 
Cys C level in the PTB +CD group was 4.014 
times higher than that of the control group after 
adjusting eGFR Cys C increased with decrease 
in eGFR in the four groups.  
 
Although atherosclerosis is a complex process, 
Genome-Wide Association Study (GWAS) 
research and candidate gene studies support the 
involvement of inflammatory mechanisms in the 
pathogenesis of atherosclerosis. Recently, 
GWAS identified a number of coronary heart 
diseases and inflammation-associated genes. 
Recent studies also showed that immune and 
inflammatory responses and endothelial 
dysfunction are key links in the pathogenesis of 
hypertension [22]. In addition, the inflammation 
hypothesis of diabetes suggests that a low 
degree of natural immunity as well as 
inflammatory factors are associated with 
diabetes [23]. There is a competition between 
pro- and anti-inflammatory signals in PTB. 
Ingestion of intracellular bacteria by 
macrophages and dendritic cells initiates the first 
important immune responses. Infected dendritic 
cells can express IL-12, TNF-α and IL-10 
cytokines [24], while macrophages produce 
mainly TNF-α, IL-10 and a small amount of IL-12 
[25]. These provoke a series of inflammatory 
reactions. 
 
From the analysis of results obtained in this 
study, chronic diseases combined with PTB 
might result in higher levels of Cys C, probably 
due to the fact that inflammation is involved in 
chronic diseases and TB. Cys C and eGFR were 
negatively correlated. Since Cys C is a cysteine 
protease inhibitor, it is more reliable than 
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creatinine and BUN in reflecting endogenous 
glomerular filtration rate. Renal impairment may 
lead to elevated Cys C, and since it involves 




The results obtained in this study suggest that 
Cys C is not only a sensitive indicator of renal 
function but also an independent factor for 
predicting the risk of pulmonary tuberculosis 
associated with some chronic diseases 
(hypertension, diabetes and cardiovascular 
diseases). Therefore, Cys C is likely to be an 
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